CBD Safety Confirmed: ACNFP's Comprehensive Review of a Hemp Derived Isolated Cannabidiol (RP427)

This evaluation is particularly crucial as CBD products have become increasingly popular, raising concerns about their safety when incorporated into food items.

Context and Purpose of the Review 

The review, commissioned by the Food Standards Agency (FSA) and Food Standards Scotland (FSS), aimed to determine the safety of a highly purified CBD isolate (over 98% purity) for use in food supplements for adults, with hemp seed oil as carrier. As CBD has surged in popularity, its inclusion in various food products has required rigorous safety evaluations to ensure consumer protection. This assessment is part of the regulatory process to ensure that novel foods are safe for consumption before being allowed on the market.

Key Findings from the ACNFP Review

The ACNFP’s review focused on the safety profile of isolated CBD under the proposed conditions of use. The high purity of the CBD isolate was a central factor in the evaluation, as it reduces the risk of contaminants that could pose health risks. The committee reviewed toxicological data, production processes, and solvent residues, all of which met the required safety standards.

Toxicological studies were crucial in identifying any potential adverse effects of CBD, particularly with long-term use. The applicant provided a range of studies, which the ACNFP scrutinised to ensure the product’s safety for consumers.

Production Process and Solvent Residues

The ACNFP also examined the production process to verify that it adheres to safety standards. This included the extraction and purification of CBD and the measures in place to prevent contamination. Solvents typically used across a wide range of extraction methodologies, had residues that were not found to be at levels of concern, further supporting the safety of the CBD isolate.

Considerations for Specific Consumer Groups

While the ACNFP concluded that isolated CBD is safe for adults under the proposed conditions, they advised that certain consumer groups should avoid the product. These groups include pregnant and breastfeeding women and individuals on medication that might interact with CBD. The committee highlighted the lack of comprehensive data on CBD’s effects in these populations, making it prudent for these groups to abstain from using CBD products. The ACNFP stressed the importance of clear labelling and consumer guidance to ensure that these at-risk groups are properly informed.

Implications for the CBD Industry

The ACNFP’s assessment marks a significant milestone for the UK CBD industry, providing a clearer pathway for the legal sale of CBD products, particularly as food supplements. The rigorous safety assessment required before market approval underscores the need for high standards in production and product safety.

The committee’s emphasis on consumer safety and the exclusion of certain groups from using CBD products also highlights the need for responsible marketing and clear communication from manufacturers. Additionally, the review reinforces the importance of continued research into the long-term effects of CBD use, as the market for these products continues to expand.

Conclusion

The ACNFP’s evaluation of isolated CBD as a novel food offers a cautiously positive outlook on its safety when used appropriately. The findings underscore the importance of high production standards and thorough safety assessments for novel food products. For consumers, particularly those in vulnerable groups, the assessment provides valuable guidance on the safe use of CBD products. For the CBD industry, it establishes a benchmark for quality and safety standards that must be met to ensure consumer protection.

For more detailed information on the ACNFP’s findings, you can view the full document here